We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Atherectomy System Treats Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 13 Feb 2014
A novel catheter uses a continuous screw to remove diseased material, as it is debulked, facilitating peripheral artery disease (PAD) treatment.

The Phoenix Atherectomy System is a system designed to restore blood flow to the thighs, ankle, and foot by removing soft plaque or calcified lesions in the arteries of PDA patients. More...
The over-the wire system uses a rotating, front-cutting element located at the distal tip of the catheter to shave material directly into the catheter. The shaved material is then continuously captured and eliminated by an internal Archimedes screw running the length of the catheter. The front-cutting design removes need to pass a catheter nosecone beyond a diseased segment before debulking.

Benefits of the system include a cut, capture, and clear mechanism of action, designed to reduce the risk of distal embolization; an over the wire (OTW) catheter design that provides needed pushability and trackability to treat occlusive lesions and navigate tortuous anatomy; and single operator use via the battery operated motor and on/off switch set in the handle, which activates the rotation of the cutting element and Archimedes screw. The Phoenix Atherectomy System is a product of AtheroMed (Menlo Park, CA, USA), and is available in multiple sizes, down to 1.8 mm in diameter with a 5F (1.2 mm) profile.

“The Phoenix Atherectomy System combines a low profile, flexible catheter shaft design with a mechanism of action that continuously clears debris from the body, so physicians can now safely perform atherectomy in vessels that previously may have been out of their reach,” said Mike MacKinnon, President and CEO of AtheroMed. “We are excited to now bring this treatment option to physicians and their patients.”

“Peripheral artery disease, especially lesions located below the knee, can be challenging to treat, even with currently available technologies,” said Thomas Davis, MD, director of the cardiac catheterization lab at St. John Hospital and Medical Center (Detroit, MI, USA). “My experience with the Phoenix device during the EASE clinical study was extremely positive, and I am excited that the device is now available as it will allow me to debulk small vessels that I may not have been able to treat in the past.”

Related Links:

AtheroMed



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Immobilization System
Cranial 4Pi Immobilization
New
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.